U.S. flag

An official website of the United States government

NM_002524.5(NRAS):c.112-24dup AND not specified

Germline classification:
Benign (1 submission)
Last evaluated:
Aug 12, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001193081.1

Allele description [Variation Report for NM_002524.5(NRAS):c.112-24dup]

NM_002524.5(NRAS):c.112-24dup

Gene:
NRAS:NRAS proto-oncogene, GTPase [Gene - OMIM - HGNC]
Variant type:
Duplication
Cytogenetic location:
1p13.2
Genomic location:
Preferred name:
NM_002524.5(NRAS):c.112-24dup
HGVS:
  • NC_000001.11:g.114714002dup
  • NG_007572.1:g.7897dup
  • NM_002524.5:c.112-24dupMANE SELECT
  • LRG_92t1:c.112-20dup
  • LRG_92:g.7897dup
  • NC_000001.10:g.115256618_115256619insG
  • NC_000001.10:g.115256623dup
  • NM_002524.3:c.112-20dupC
  • NM_002524.4:c.112-20dup
Links:
dbSNP: rs780595451
NCBI 1000 Genomes Browser:
rs780595451
Molecular consequence:
  • NM_002524.5:c.112-24dup - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001361670Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Benign
(Aug 12, 2019)
germlineclinical testing

PubMed (5)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.

Kim D, Hong YS, Kim JE, Kim KP, Lee JL, Chun SM, Kim J, Jang SJ, Kim TW.

Cancer Res Treat. 2017 Jan;49(1):37-43. doi: 10.4143/crt.2016.069. Epub 2016 Apr 27.

PubMed [citation]
PMID:
27121720
PMCID:
PMC5266405

Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.

Ogura T, Kakuta M, Yatsuoka T, Nishimura Y, Sakamoto H, Yamaguchi K, Tanabe M, Tanaka Y, Akagi K.

Oncol Rep. 2014 Jul;32(1):50-6. doi: 10.3892/or.2014.3165. Epub 2014 May 6.

PubMed [citation]
PMID:
24806883
See all PubMed Citations (5)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001361670.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)

Description

Variant summary: NRAS c.112-20dupC alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00015 in 273884 control chromosomes, predominantly at a frequency of 0.00026 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 104 fold of the estimated maximal expected allele frequency for a pathogenic variant in NRAS causing Noonan Syndrome and Related Conditions phenotype (2.5e-06), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. To our knowledge, no occurrence of c.112-20dupC in individuals affected with Noonan Syndrome and Related Conditions and no experimental evidence demonstrating its impact on protein function have been reported. A ClinVar submission (evaluation after 2014) cites the variant as likely benign. Based on the evidence outlined above, the variant was classified as benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024